Biotech Values

[DewDiligence]

…I predict a Novartis munch [of MNTA] within 12 months. Cash+CVR's [contingent value rights] for Copaxone.

The FDA’s willingness to approve Amphastar’s Lovenox would seem to increase the likelihood to some degree that the FDA will approve MNTA’s Copaxone, and that’s how I would expect MNTA’s BoD to view the situation. Thus, there may be strong resistance to the idea of accepting a lowball up-front with a CVR for Copaxone.